These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38092666)

  • 21. Evaluating immunity to SARS-CoV-2 in nursing home residents using saliva IgG.
    Katz MJ; Heaney CD; Pisanic N; Smith L; Bigelow BF; Sheikh F; Boudreau A; Kruczynski K; Hsu YJ; Salinas AB; Cosgrove SE; Rock C
    J Am Geriatr Soc; 2022 Mar; 70(3):659-668. PubMed ID: 35038344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2 antibody vaccine response in Inflammatory Bowel Disease patients with positive anti-nucleocapsid serology or history of COVID-19 infection.
    Hoyois A; Gulkilik C; Mekkaoui L; Dahma H; Wambacq V; Minsart C; Rosewick N; Liefferinckx C; Amininejad L; Van Gossum A; Cremer A; Vandenberg O; Franchimont D
    Acta Gastroenterol Belg; 2024; 87(2):263-273. PubMed ID: 39210758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of intranasal vaccine based on SARS-CoV-2 spike protein during primary and booster immunizations in mice.
    Yang H; Xie Y; Li S; Bao C; Wang J; Li C; Nie J; Quan Y
    Hum Vaccin Immunother; 2024 Dec; 20(1):2364519. PubMed ID: 38880868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.
    Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G
    Front Immunol; 2021; 12():737083. PubMed ID: 34539673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of COVID-19 mRNA vaccine symptomatic breakthrough infections during Omicron circulation in adults with or without infection prior to vaccination.
    Durier C; Ninove L; van der Werf S; Lefebvre M; Desaint C; Bauer R; Attia M; Lecompte AS; Lachatre M; Maakaroun-Vermesse Z; Nicolas JF; Verdon R; Kiladjian JJ; Loubet P; Schmidt-Mutter C; Corbin V; Ansart S; Melica G; Resch M; Netzer E; Kherabi Y; Tardieu R; Lelièvre JD; Tartour E; Meyer L; de Lamballerie X; Launay O;
    Infect Dis Now; 2024 Aug; 54(5):104886. PubMed ID: 38494117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variant-Specific IgA Protects Against Omicron Infection.
    Goh YS; Fong SW; Hor PX; Loh CY; Wang B; Salleh SNM; Ngoh EZX; Lee RTC; Poh XY; Rao S; Chia PY; Ong SWX; Lee TH; Lim C; Teo J; Pada S; Sun LJ; Ong DLS; Somani J; Lee ES; Maurer-Stroh S; Wang CI; Leo YS; Lye DC; Young BE; Ng LFP; Renia L; ;
    J Infect Dis; 2024 Aug; 230(2):e287-e291. PubMed ID: 37996071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterologous SARS-CoV-2 booster vaccine for individuals with hematological malignancies after a primary SARS-CoV-2 mRNA vaccine series.
    Sherman AC; van Haren SD; Borberg E; Swank Z; Aleissa M; Tong A; Rooks R; Kanwal U; Levine H; Yates B; Izaguirre N; Ryff K; Thomas S; Parisi L; Li X; Walt DR; Levy O; Walsh SR; Issa NC; Baden LR
    Vaccine; 2024 Sep; 42(22):126054. PubMed ID: 38862310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates.
    Gagne M; Flynn BJ; Andrew SF; Marquez J; Flebbe DR; Mychalowych A; Lamb E; Davis-Gardner ME; Burnett MR; Serebryannyy LA; Lin BC; Ziff ZE; Maule E; Carroll R; Naisan M; Jethmalani Y; Pessaint L; Todd JM; Doria-Rose NA; Case JB; Dmitriev IP; Kashentseva EA; Ying B; Dodson A; Kouneski K; O'Dell S; Wali B; Ellis M; Godbole S; Laboune F; Henry AR; Teng IT; Wang D; Wang L; Zhou Q; Zouantchangadou S; Van Ry A; Lewis MG; Andersen H; Kwong PD; Curiel DT; Roederer M; Nason MC; Foulds KE; Suthar MS; Diamond MS; Douek DC; Seder RA
    Nat Immunol; 2024 Oct; 25(10):1913-1927. PubMed ID: 39227514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody Response Before and After the Booster Dose of Inactivated Corona Vaccine in Antibody Deficient Patients.
    Movahedi M; Movahedi M; Parvaneh N; Abolhassani H; Mahdavi M; Mosavikhorshidi MS; Alizadeh F; Shokri M; Kalantari A
    Iran J Allergy Asthma Immunol; 2024 Apr; 23(2):158-167. PubMed ID: 38822511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preservation of Anti-SARS-CoV-2 Neutralizing Antibodies in Breast Milk: Impact of Maternal COVID-19 Vaccination and Infection.
    Suteerojntrakool O; Mekangkul E; Maitreechit D; Khabuan S; Sodsai P; Hirankarn N; Thumbovorn R; Chomtho S
    Breastfeed Med; 2024 May; 19(5):340-348. PubMed ID: 38506333
    [No Abstract]   [Full Text] [Related]  

  • 32. Intranasal administration of unadjuvanted SARS-CoV-2 spike antigen boosts antigen-specific immune responses induced by parenteral protein subunit vaccine prime in mice and hamsters.
    Agbayani G; Akache B; Renner TM; Tran A; Stuible M; Dudani R; Harrison BA; Duque D; Bavananthasivam J; Deschatelets L; Hemraz UD; Régnier S; Durocher Y; McCluskie MJ
    Eur J Immunol; 2024 Jun; 54(6):e2350620. PubMed ID: 38561974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines.
    Chan RWY; Liu S; Cheung JY; Tsun JGS; Chan KC; Chan KYY; Fung GPG; Li AM; Lam HS
    Front Immunol; 2021; 12():744887. PubMed ID: 34712232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up.
    Salehi M; Alavi Darazam I; Nematollahi A; Alimohammadi M; Pouya S; Alimohammadi R; Khajavirad N; Porgoo M; Sedghi M; Mahdi Sepahi M; Azimi M; Hosseini H; Mahmoud Hashemi S; Dehghanizadeh S; Khoddami V
    Int Immunopharmacol; 2024 Jun; 134():112192. PubMed ID: 38761778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2.
    Townsend JP; Hassler HB; Sah P; Galvani AP; Dornburg A
    Proc Natl Acad Sci U S A; 2022 Aug; 119(31):e2204336119. PubMed ID: 35858382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Impact of Time between Booster Doses on Humoral Immune Response in Solid Organ Transplant Recipients Vaccinated with BNT162b2 Vaccines.
    Hamm SR; Loft JA; Pérez-Alós L; Heftdal LD; Hansen CB; Møller DL; Pries-Heje MM; Hasselbalch RB; Fogh K; Hald A; Ostrowski SR; Frikke-Schmidt R; Sørensen E; Hilsted L; Bundgaard H; Garred P; Iversen K; Perch M; Sørensen SS; Rasmussen A; Sabin CA; Nielsen SD
    Viruses; 2024 May; 16(6):. PubMed ID: 38932153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
    Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
    Front Immunol; 2021; 12():786554. PubMed ID: 35003104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.
    Corbett KS; Nason MC; Flach B; Gagne M; O'Connell S; Johnston TS; Shah SN; Edara VV; Floyd K; Lai L; McDanal C; Francica JR; Flynn B; Wu K; Choi A; Koch M; Abiona OM; Werner AP; Moliva JI; Andrew SF; Donaldson MM; Fintzi J; Flebbe DR; Lamb E; Noe AT; Nurmukhambetova ST; Provost SJ; Cook A; Dodson A; Faudree A; Greenhouse J; Kar S; Pessaint L; Porto M; Steingrebe K; Valentin D; Zouantcha S; Bock KW; Minai M; Nagata BM; van de Wetering R; Boyoglu-Barnum S; Leung K; Shi W; Yang ES; Zhang Y; Todd JM; Wang L; Alvarado GS; Andersen H; Foulds KE; Edwards DK; Mascola JR; Moore IN; Lewis MG; Carfi A; Montefiori D; Suthar MS; McDermott A; Roederer M; Sullivan NJ; Douek DC; Graham BS; Seder RA
    Science; 2021 Sep; 373(6561):eabj0299. PubMed ID: 34529476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice.
    Slamanig S; González-Domínguez I; Chang LA; Lemus N; Lai TY; Martínez JL; Singh G; Dolange V; Abdeljawad A; Kowdle S; Noureddine M; Warang P; Singh G; Lee B; García-Sastre A; Krammer F; Schotsaert M; Palese P; Sun W
    EBioMedicine; 2024 Jul; 105():105185. PubMed ID: 38848648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune response against the SARS-CoV-2 spike protein in cancer patients after COVID-19 vaccination during the Omicron wave: a prospective study.
    Muñoz-Gómez MJ; Ryan P; Quero-Delgado M; Martin-Vicente M; Cuevas G; Valencia J; Jiménez E; Blanca-López N; Lara-Álvarez MÁ; Hernández-Rivas JÁ; Redondo G; Mas V; Sepúlveda-Crespo D; Vázquez M; Torres-Macho J; Martínez I; Resino S
    J Infect Public Health; 2024 Jul; 17(7):102473. PubMed ID: 38865774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.